First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Down's syndrome occurs when a person has three, rather than two copies of chromosome 21; or the specific area of chromosome 21 implicated in causing Down's syndrome. It is the commonest congenital cause of mental disability and also leads to numerous metabolic and structural problems. It can be life-threatening, or lead to considerable ill health, although some individuals have only mild problems and can lead relatively normal lives. Having a baby with Down's syndrome is likely to have a significant impact on family life.Non-invasive screening based on biochemical analysis of maternal serum or urine, or fetal ultrasound measurements, allows estimates of the risk of a pregnancy being affected and provides information to guide decisions about definitive testing.Before agreeing to screening tests, parents need to be fully informed about the risks, benefits and possible consequences of such a test. This includes subsequent choices for further tests they may face, and the implications of both false positive and false negative screening tests (i.e. invasive diagnostic testing, and the possibility that a miscarried fetus may be chromosomally normal). The decisions that may be faced by expectant parents inevitably engender a high level of anxiety at all stages of the screening process, and the outcomes of screening can be associated with considerable physical and psychological morbidity. No screening test can predict the severity of problems a person with Down's syndrome will have. OBJECTIVES: To estimate and compare the accuracy of first trimester ultrasound markers alone, and in combination with first trimester serum tests for the detection of Down's syndrome. SEARCH METHODS: We carried out extensive literature searches including MEDLINE (1980 to 25 August 2011), Embase (1980 to 25 August 2011), BIOSIS via EDINA (1985 to 25 August 2011), CINAHL via OVID (1982 to 25 August 2011), and The Database of Abstracts of Reviews of Effects (the Cochrane Library 2011, Issue 7). We checked reference lists and published review articles for additional potentially relevant studies. SELECTION CRITERIA: Studies evaluating tests of first trimester ultrasound screening, alone or in combination with first trimester serum tests (up to 14 weeks' gestation) for Down's syndrome, compared with a reference standard, either chromosomal verification or macroscopic postnatal inspection. DATA COLLECTION AND ANALYSIS: Data were extracted as test positive/test negative results for Down's and non-Down's pregnancies allowing estimation of detection rates (sensitivity) and false positive rates (1-specificity). We performed quality assessment according to QUADAS criteria. We used hierarchical summary ROC meta-analytical methods to analyse test performance and compare test accuracy. Analysis of studies allowing direct comparison between tests was undertaken. We investigated the impact of maternal age on test performance in subgroup analyses. MAIN RESULTS: We included 126 studies (152 publications) involving 1,604,040 fetuses (including 8454 Down's syndrome cases). Studies were generally good quality, although differential verification was common with invasive testing of only high-risk pregnancies. Sixty test combinations were evaluated formed from combinations of 11 different ultrasound markers (nuchal translucency (NT), nasal bone, ductus venosus Doppler, maxillary bone length, fetal heart rate, aberrant right subclavian artery, frontomaxillary facial angle, presence of mitral gap, tricuspid regurgitation, tricuspid blood flow and iliac angle 90 degrees); 12 serum tests (inhibin A, alpha-fetoprotein (AFP), free beta human chorionic gonadotrophin (ßhCG), total hCG, pregnancy-associated plasma protein A (PAPP-A), unconjugated oestriol (uE3), disintegrin and metalloprotease 12 (ADAM 12), placental growth factor (PlGF), placental growth hormone (PGH), invasive trophoblast antigen (ITA) (synonymous with hyperglycosylated hCG), growth hormone binding protein (GHBP) and placental protein 13 (PP13)); and maternal age. The most frequently evaluated serum markers in combination with ultrasound markers were PAPP-A and free ßhCG.Comparisons of the 10 most frequently evaluated test strategies showed that a combined NT, PAPP-A, free ßhCG and maternal age test strategy significantly outperformed ultrasound markers alone (with or without maternal age) except nasal bone, detecting about nine out of every 10 Down's syndrome pregnancies at a 5% false positive rate (FPR). In both direct and indirect comparisons, the combined NT, PAPP-A, free ßhCG and maternal age test strategy showed superior diagnostic accuracy to an NT and maternal age test strategy (P < 0.0001). Based on the indirect comparison of all available studies for the two tests, the sensitivity (95% confidence interval) estimated at a 5% FPR for the combined NT, PAPP-A, free ßhCG and maternal age test strategy (69 studies; 1,173,853 fetuses including 6010 with Down's syndrome) was 87% (86 to 89
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Whiting, P., Rutjes, A. W., Reitsma, J. B., Bossuyt, P. M., & Kleijnen, J. (2003) · BMC Medical Research Methodology · doi:10.1186/1471-2288-3-25 · Cited by 3,592
Evaluating non-randomised intervention studies
Deeks, J., Dinnes, J., D'Amico, R., Sowden, A., Sakarovitch, C., Song, F., Petticrew, M., & Altman, D. (2003) · Health Technology Assessment · doi:10.3310/hta7270 · Cited by 2,907
Self-citationSnijders, R., Noble, P., Sebire, N., Souka, A., & Nicolaides, K. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11280-6 · Cited by 1,572
Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities
Nicolaides, K. H. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.03.090 · Cited by 626 · cited 1×
“Nicolaides 2004 {published data only} Nicolaides KH. Nuchal translucency and other firsttrimester sonographic markers of chromosomal 56First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening (Review) Copyright © 2017 The Cochrane…”
BackgroundMaiz, N., Valencia, C., Kagan, K. O., Wright, D., & Nicolaides, K. H. (2009) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.6330 · Cited by 206
Kagan, K. O., Valencia, C., Livanos, P., Wright, D., & Nicolaides, K. H. (2009) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.6264 · Cited by 175
Relation between increased fetal nuchal translucency thickness and chromosomal defects
Kagan, K. O., Avgidou, K., Molina, F. S., Gajewska, K., & Nicolaides, K. H. (2006) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000191301.63871.c6 · Cited by 171
Metzenbauer, M., Hafner, E., Schuchter, K., & Philipp, K. (2002) · Ultrasound in Obstetrics & Gynecology · doi:10.1046/j.1469-0705.2002.00655.x · Cited by 79
Spencer, K., Liao, A. W., Ong, C. Y. T., Geerts, L., & Nicolaides, K. H. (2001) · Prenatal Diagnosis · doi:10.1002/pd.148 · Cited by 36
Cited by
Salameh, J.-P., Bossuyt, P. M., McGrath, T. A., Thombs, B. D., Hyde, C. J., Macaskill, P., Deeks, J. J., Leeflang, M., Korevaar, D. A., Whiting, P., et al. (2020) · BMJ · doi:10.1136/bmj.m2632 · Cited by 719
Self-citationScreening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin, Number 226
American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Obstetrics, Committee on Genetics, & Society for Maternal-Fetal Medicine (2020) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000004084 · Cited by 552
Buijtendijk, M. F., Bet, B. B., Leeflang, M. M., Shah, H., Reuvekamp, T., Goring, T., Docter, D., Timmerman, M. G., Dawood, Y., Lugthart, M. A., et al. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014715.pub2 · Cited by 47
Walker, M. C., Willner, I., Miguel, O. X., Murphy, M. S. Q., El-Chaâr, D., Moretti, F., Dingwall Harvey, A. L. J., Rennicks White, R., Muldoon, K. A., Carrington, A. M., et al. (2022) · PLOS ONE · doi:10.1371/journal.pone.0269323 · Cited by 31
Metadata
- Authors
- Alldred, S. K., Takwoingi, Y., Guo, B., Pennant, M., Deeks, J. J., Neilson, J. P., & Alfirevic, Z.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2017-03-15
- Volume
- 2017
- Issue
- 3
- Pages
- CD012600-CD012600
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2602126563
- Cited by
- 90
- References
- 9
- FWCI
- 8.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening. https://app.cochat.ai/papers/10.1002/14651858.cd012600
- The paper
- Alldred, S. K., Takwoingi, Y., Guo, B., Pennant, M., Deeks, J. J., Neilson, J. P., & Alfirevic, Z. (2017). First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd012600
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.